High Growth Tech Stocks in South Korea Featuring Three Top Picks

The South Korean market has remained flat over the past week but has shown a 6.4% increase over the past year, with earnings forecasted to grow by 31% annually. In this context, identifying high growth tech stocks involves looking for companies that are well-positioned to capitalize on robust earnings potential and demonstrate resilience in fluctuating market conditions.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
IMLtd	21.80%	111.43%	★★★★★★
Seojin SystemLtd	33.39%	49.13%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
NEXON Games	29.64%	66.98%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
Devsisters	29.08%	63.02%	★★★★★★
Park Systems	23.21%	34.63%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★
UTI	114.97%	134.60%	★★★★★★

Click here to see the full list of 48 stocks from our KRX High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

WemadeLtd (KOSDAQ:A112040)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Wemade Co.,Ltd. is a company that develops and publishes games both in South Korea and internationally, with a market cap of ₩1.25 trillion.

Operations: The company's primary revenue stream is its gaming business, generating ₩684.76 billion.

Wemade Ltd., navigating through the competitive landscape of South Korea's tech sector, has shown a notable turnaround with its recent financials indicating a shift from a net loss to a modest profit within six months. Despite revenue growth projections trailing slightly behind the broader market at 9.5% annually compared to 10.5%, the company's earnings are expected to surge by an impressive 105.7% per year over the next three years, signaling potential robust internal improvements and market adaptation strategies. Particularly noteworthy is Wemade's commitment to innovation, as evidenced by their significant R&D expenditures aimed at solidifying their foothold in high-growth tech arenas—a strategic move that could redefine their market position and investor appeal in forthcoming periods.

• Click to explore a detailed breakdown of our findings in WemadeLtd's health report.

• Learn about WemadeLtd's historical performance.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩19.60 billion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to ₩90.79 million. With a market cap of approximately ₩19.60 billion, it focuses on innovative biotechnological solutions.

ALTEOGEN stands out in South Korea's tech sector with its aggressive growth trajectory, evidenced by a forecasted annual revenue increase of 64.2%, significantly outpacing the broader market's 10.5%. This rapid expansion is underpinned by substantial R&D investments, which not only highlight the company’s commitment to innovation but also strategically position it to capitalize on emerging biotech advancements. Despite current unprofitability, ALTEOGEN is expected to pivot into profitability within three years, with earnings potentially growing at an annual rate of 99.5%. These figures suggest a robust internal strategy geared towards capturing and expanding market share in a highly competitive industry landscape.

• Unlock comprehensive insights into our analysis of ALTEOGEN stock in this health report.

• Examine ALTEOGEN's past performance report to understand how it has performed in the past.

Solum (KOSE:A248070)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Solum Co., Ltd. manufactures and markets power modules, digital tuners, and electronic shelf labels to customers in South Korea and internationally, with a market cap of ₩984.07 billion.

Operations: The company generates revenue primarily through its ICT Business and Electronic Components Division, with the latter contributing significantly more at ₩1.16 trillion compared to ₩470.84 billion from the former.

Solum's strategic maneuvers in South Korea's tech landscape are underscored by its recent announcement of a KRW 20 billion share repurchase program, aimed at stabilizing stock prices and enhancing shareholder value. This move complements the company’s robust forecasted earnings growth of 36.8% per year, significantly outstripping the broader Korean market's growth rate of 30.1%. Despite challenges like a high debt level and past negative earnings growth of -37.1%, Solum is navigating with an aggressive R&D investment strategy, which is critical for sustaining its competitive edge in the fast-evolving tech sector. The firm’s commitment to innovation is evident from its projected revenue increase of 14.3% annually, surpassing the market average of 10.5%, positioning it well for future technological advancements and market demands.

• Get an in-depth perspective on Solum's performance by reading our health report here.

• Understand Solum's track record by examining our Past report.

Seize The Opportunity

• Navigate through the entire inventory of 48 KRX High Growth Tech and AI Stocks here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com